Hepatitis B : FDA and EMA regulatory review of VBI’s 3-antigen prophylactic HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021
COVID-19 : Initial data from ongoing Phase 1/2 study of VBI-2902, VBI’s monovalent COVID-19 vaccine candidate, expected by end of Q2 2021
Glioblastoma : Additional tumor response data, 6-month and 12-month overall survival data from the ongoing Phase 2a study of VBI-1901 in recurrent GBM patients expected Q2 2021
$133.6 million in cash, cash equivalents, and short-term investments at the end of Q1 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.